report_lead_image_with_gradient.png
Q2 2026

Pharma Biotools Report: Steady Top Line as Frontier AI Labs Move In

Download this Report
To download this report, please complete the form below

PitchBook clients can access the full report and Excel data pack via the Research Center on the PitchBook Platform.

Pharma biotools VC holds at $1.3 billion as deal count drops 19%

Pharma biotools VC investment held at $1.3 billion across 126 deals in Q2 2026, marking the sixth straight quarter above $1 billion. Deal count fell 19% from Q1, however, dropping back to post-pandemic norms, as the broader biopharma funding recovery has yet to reach the tools sector. Services led all segments at $502 million, powered by Cellares’ Series D extension ahead of a planned 2027 IPO. Platforms & reagents overtook in silico discovery for the first time in recent memory, taking second place at $330 million across 29 deals. On the M&A side, Merck KGaA’s $11.3 billion agreement to acquire Bio-Techne headlined strategic consolidation, as established players have been buying up reagent and assay platforms to control complete discovery workflows.

The bigger story is where the money is going: VC is bifurcating across the vertical. Asset-light AI platforms are capturing outsized early rounds. Chai Discovery’s $400 million Series C landed just after quarter-end, with Lila Sciences reportedly pursuing a $2 billion Series B. Meanwhile, capital-intensive platforms are scaling toward a stricter exit bar. Tech-oriented syndicates are driving these mega-rounds, and traditional biopharma venture funds have largely stayed out. Frontier AI labs are emerging as a new acquirer class, with NVIDIA’s BioNeMo Agent Toolkit commoditizing baseline model capability from below. The Q2 2026 Pharma Biotools Report includes segment-level deal data, valuation benchmarks, and exit analysis.


Annualized H1 2026 deal activity falls behind 2025 totals as the vertical lags the biopharma recovery.



Table of contents
Pharma biotools landscape 3
Quarterly analysis 4
       Key takeaways 4
       VC activity 4
       Industry trends 8
       AI themes 9
       Conclusions 10
Pharma biotools VC deal summary 29
References 30